Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy NGM Biopharmaceuticals (NGM) stocks in Canada

Learn how to easily invest in NGM Biopharmaceuticals stocks.

NGM Biopharmaceuticals is a biotechnology business based in the US. NGM Biopharmaceuticals stocks (NGM.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $21.7 – a decrease of 6.06% over the previous week. NGM Biopharmaceuticals employs 210 staff and has a trailing 12-month revenue of around $76.7 million.

How to buy shares in NGM Biopharmaceuticals

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – NGM – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Is it a good time to buy NGM Biopharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

How has Coronavirus impacted NGM Biopharmaceuticals's stock price?

Since the stock market crash in March caused by coronavirus, NGM Biopharmaceuticals's stock price has had significant negative movement.

Its last market close was $15.96, which is 1.42% down on its pre-crash value of $16.19 and 72.63% up on the lowest point reached during the March crash when the stocks fell as low as $9.245.

If you had bought $1,000 worth of NGM Biopharmaceuticals stocks at the start of February 2020, those stocks would have been worth $693.37 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $939.41.

NGM Biopharmaceuticals stock price (NASDAQ:NGM)

Use our graph to track the performance of NGM stocks over time.

NGM Biopharmaceuticals shares at a glance

Information last updated 2022-01-11.
Latest market close$15.96
52-week range$14.90 - $32.12
50-day moving average $18.71
200-day moving average $21.56
Wall St. target price$35.83
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-1.62

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Feature Table description
FREE TRADES
Wealthsimple Trade
Finder Rating:
★★★★★
3.9 / 5
$0
$0
Stocks, ETFs
Get 2 free stocks (total value up to $9,000) when you deposit and trade $150.
Pay no commissions when you trade Canadian stocks and ETFs with Wealthsimple Trade.
Scotia iTRADE
Finder Rating:
★★★★★
3.8 / 5
$4.99 - $9.99
$0
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
Buy, sell and trade ETFs, Equities, Options and more with competitive commissions.
Interactive Brokers
Finder Rating:
★★★★★
4.1 / 5
Min. $1.00, Max. 0.5%
$0
Stocks, Bonds, Options, ETFs, Currencies, Futures
Extensive trading capabilities and global investment tracking.
Access market data 24 hours a day, six days a week and invest in global stocks, options, futures, currencies, bonds and funds from one single account.
OFFER
CIBC Investor's Edge
Finder Rating:
★★★★★
4 / 5
$4.95 - $6.95
$0 if conditions met, otherwise $100/year
Stocks, Bonds, Options, Mutual Funds, ETFs
Get up to $2,000 cash back. Conditions apply. Offer ends March 1, 2022.
An intuitive and easy-to-use platform with access to a variety of tools that help you make smart decisions and trade with confidence.
Questrade
Finder Rating:
★★★★★
4.2 / 5
$4.95 - $9.95
$0
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
Opt for self-directed investing and save on fees or get a pre-built portfolio and take some of the guesswork out.
Qtrade Direct Investing
Finder Rating:
★★★★★
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get a $50 bonus when you open a new RRSP, TFSA or RESP and start pre-authorized contributions of at least $200/month. Valid until March 1, 2022.
Qtrade Direct Investing offers low trading commissions and an easy-to-use platform with access to powerful tools and a wide selection of investment options. Trade 100 ETFs free of charge and thousands more for $8.75 or lower.
loading

Compare up to 4 providers

Online stock trading

NGM Biopharmaceuticals price performance over time

Historical closes compared with the close of $15.96 from 2022-01-14

1 week (2022-01-06) -5.79%
1 month (2021-12-16) -9.06%
3 months (2021-10-15) -18.90%
6 months (2021-07-16) -23.64%
1 year (2021-01-15) -41.50%
2 years (2020-01-16) -15.96%
3 years (2019-01-12) N/A
5 years (2017-01-12) N/A

NGM Biopharmaceuticals financials

Revenue TTM $76.7 million
Gross profit TTM $-76,604,000
Return on assets TTM -20.41%
Return on equity TTM -38.4%
Profit margin -157.9%
Book value $4.56
Market capitalisation $1.3 billion

TTM: trailing 12 months

NGM Biopharmaceuticals share dividends

We're not expecting NGM Biopharmaceuticals to pay a dividend over the next 12 months.

NGM Biopharmaceuticals share price volatility

Over the last 12 months, NGM Biopharmaceuticals's shares have ranged in value from as little as $14.9 up to $32.12. A popular way to gauge a stock's volatility is its "beta".

NGM.US volatility(beta: 1.78)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while NGM Biopharmaceuticals's is 1.7751. This would suggest that NGM Biopharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

NGM Biopharmaceuticals overview

NGM Biopharmaceuticals, Inc. , a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company's product candidates include Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trials for the treatment of non-alcoholic steatohepatitis (NASH); and MK-3655, an agonistic antibody that activates fibroblast growth factor receptor 1c-beta-klotho, which is in Phase IIb clinical trial for use in the treatment of type 2 diabetes and NASH. Its products under development also comprise NGM120, an inhibitory antibody binding glial cell-derived neurotrophic factor receptor alpha-like that is in Phase Ib clinical trials to inhibit growth differentiation factor GDF15 levels on cancer anorexia/cachexia syndrome; NGM621, an antibody in Phase II clinical trials for the treatment of geographic atrophy; and NGM707 and NGM438, which are in preclinical investigational studies for the treatment of advanced solid tumors. The company has research collaboration, product development, and license agreements with Merck Sharp & Dohme Corp. ; and a collaboration agreement with Merck & Co. , Inc.

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs and forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Ask an Expert

You must be logged in to post a comment.

Go to site